相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)
Eishi Baba et al.
GASTRIC CANCER (2023)
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
Y. Kubota et al.
ESMO OPEN (2023)
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET ONCOLOGY (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
F. Lordick et al.
ANNALS OF ONCOLOGY (2022)
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U. Sahin et al.
ANNALS OF ONCOLOGY (2021)
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
Antonio Pellino et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Feng-Hua Wang et al.
CANCER COMMUNICATIONS (2021)
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry
Florian Huemer et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET ONCOLOGY (2019)
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Tuereci et al.
ANNALS OF ONCOLOGY (2019)
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
Christoph Rohde et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
Ugur Sahin et al.
EUROPEAN JOURNAL OF CANCER (2018)
103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
D Moran et al.
ANNALS OF ONCOLOGY (2018)
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Maria Apicella et al.
ONCOTARGET (2017)
Tight junction-related human diseases
Norimasa Sawada
PATHOLOGY INTERNATIONAL (2013)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Ugur Sahin et al.
CLINICAL CANCER RESEARCH (2008)
claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing
T Niimi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
